Medley (4480) AI Stock Analysis

• Market Cap: €69.79B
• Dividend Yield: N/A
• Average Volume (3M): 504.45K
• Price to Earnings (P/E): 48.0
• Beta (1Y): 0.60
• Revenue Growth: 31.95%
• EPS Growth: -40.95%
• Country: JP
• Employees: 1,487
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 14.67
• Shares Outstanding: 32,738,600
• 10 Day Avg. Volume: 497,800
• 30 Day Avg. Volume: 504,450
• PEG Ratio: 5.33
• Price to Book (P/B): 6.16
• Price to Sales (P/S): 4.25
• P/FCF Ratio: 52.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €4,499.19
• Price Target Upside: 80.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ¥2,772.00 ▲(11.46% Upside)

Medley, Inc.'s strong financial performance is the primary driver of its stock score, supported by robust revenue and profit growth. However, technical indicators suggest potential short-term volatility, and the high P/E ratio indicates overvaluation concerns. The absence of a dividend yield further impacts the valuation score.

Medley Business Overview & Revenue Model

Company Description

Medley, Inc. operates platforms for recruitment and medical businesses in Japan. It operates through three segments: HR Platform Business, Medical Platform Business, and New Services. The company manages JobMedley, a human resource recruitment system for medical and healthcare, and related businesses; CLINICS Telemedicine, a telemedicine system for patients and medical institutions; CLINICS, a cloud medical support system; Pharms pharmacy window support systems; and MEDLEY, a medical information service for patients, as well as Kaigo-no Honne, a website to search nursing care facilities. It also conducts proof-of-concept testing for pharms. Medley, Inc. was incorporated in 2009 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Medley generates revenue primarily through subscription fees for its telehealth platform, where healthcare providers pay for access to the software and services that facilitate virtual care. Additionally, the company earns income from per-visit fees charged to patients for virtual consultations. Key revenue streams include partnerships with healthcare organizations and insurance companies that integrate Medley's services into their offerings, as well as monetization of data insights gathered from patient interactions to improve healthcare delivery and outcomes. The company's growth is further supported by strategic collaborations with technology firms to enhance its platform capabilities and expand its market reach.

Medley Financial Statement Overview

Summary

Medley, Inc. is in a strong financial position with impressive revenue and profit growth, stable cash flow generation, and a solid balance sheet. However, there are concerns about operational efficiency and investment returns.

Income Statement

Medley, Inc. has demonstrated strong revenue growth, with a significant increase from 2023 to 2024, indicating a positive growth trajectory. The gross profit margin remains robust, and the net profit margin is healthy, reflecting efficient cost management. However, the slight decline in EBIT margin suggests potential pressure on operational efficiency.

Balance Sheet

The company's balance sheet is stable, with a solid equity base and a healthy debt-to-equity ratio, indicating low financial leverage. The equity ratio is also strong, reflecting a well-capitalized structure. However, the increase in total liabilities warrants monitoring, as it could impact future financial flexibility.

Cash Flow

Medley, Inc. exhibits strong cash flow generation, with positive free cash flow and a favorable operating cash flow to net income ratio. The free cash flow growth rate is commendable, suggesting efficient capital expenditure management. Despite this, the significant negative investing cash flow highlights substantial investments, which could pose risks if not yielding expected returns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.06B	29.30B	20.53B	14.19B	10.86B	6.83B
Gross Profit	20.74B	18.92B	13.59B	9.72B	6.99B	4.67B
EBITDA	5.03B	4.00B	4.50B	2.14B	1.25B	586.57M
Net Income	1.44B	2.80B	2.57B	1.02B	563.00M	455.99M
Balance Sheet
Total Assets	47.42B	45.20B	25.43B	21.81B	20.21B	15.52B
Cash, Cash Equivalents and Short-Term Investments	13.52B	19.00B	15.35B	14.42B	14.29B	14.05B
Total Debt	18.27B	15.18B	1.66B	2.38B	3.11B	4.18B
Total Liabilities	29.36B	24.98B	7.79B	6.64B	6.16B	5.80B
Stockholders Equity	18.07B	20.21B	17.55B	15.08B	13.97B	9.72B
Cash Flow
Free Cash Flow	0.00	2.38B	3.47B	1.64B	796.39M	591.87M
Operating Cash Flow	0.00	2.45B	3.87B	2.01B	1.04B	805.76M
Investing Cash Flow	0.00	-10.72B	-1.66B	-751.00M	-3.29B	-283.15M
Financing Cash Flow	0.00	11.90B	-1.22B	-927.00M	2.22B	9.05B

Medley Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2487.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4480, the sentiment is Neutral. The current price of 2487 is above the 20-day moving average (MA) of 2302.60, above the 50-day MA of 2342.90, and below the 200-day MA of 2922.08, indicating a neutral trend. The MACD of 77.45 indicates Negative momentum. The RSI at 56.58 is Neutral, neither overbought nor oversold. The STOCH value of 77.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4480.

Medley Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2175	68 Neutral	¥117.42B	15.23	―	2.15%	7.27%	13.10%
4480	67 Neutral	€69.79B	48.02	8.79%	―	31.95%	-40.95%
3939	67 Neutral	¥25.94B	23.35	―	1.42%	9.85%	20.83%
4483	63 Neutral	¥274.09B	44.55	―	0.38%	20.55%	48.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4263	45 Neutral	¥15.47B	―	―	―	39.30%	32.06%
3902	43 Neutral	¥17.43B	-23.82	―	1.31%	6.17%	-8918.66%

Medley Corporate Events

Medley, Inc. Reports Extraordinary Loss from Subsidiary Merger

Medley, Inc. announced an extraordinary loss due to an absorption-type merger with its wholly owned subsidiaries, including AxisRoot Holdings, Axis, Inc., Axis Innovation, Inc., and Pacific Medical, Inc. The merger resulted in a loss on extinguishment of tie-in shares amounting to 2,882 million yen, recorded in the company’s non-consolidated financial statements for the nine months ended September 30, 2025. However, this loss will not impact the consolidated profit and loss as it will be eliminated in the consolidated financial statements.

The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2181.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

Medley, Inc. Announces Strategic Share Repurchase Plan

Medley, Inc. announced a share repurchase plan to buy back up to 1.5 million of its common shares, representing 4.8% of its total issued shares, excluding treasury shares. This strategic move aims to implement a flexible capital policy and enhance shareholder returns, reflecting the company’s proactive approach to market dynamics and shareholder interests.

The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2181.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

Medley, Inc. Revises 2025 Financial Forecast Downward

Medley, Inc. has revised its financial forecast for the fiscal year ending December 2025, anticipating lower net sales and profits compared to previous estimates. The revision is attributed to unreported hiring decisions in its HR platform business and lower-than-expected settlement income, impacting its operating and ordinary profits.

The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2181.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

Medley, Inc. Reports Increased Sales but Declining Profits for 2025

Medley, Inc. reported its consolidated financial results for the nine months ending September 30, 2025, showing a significant increase in net sales by 27.2% year-on-year to ¥27,536 million. However, the company experienced a decline in operating profit and ordinary profit by 31.7% and 54.9%, respectively, indicating challenges in maintaining profitability despite revenue growth. The company also revised its financial forecast for the full year, expecting a decrease in profit attributable to owners by 53.5%, which may impact stakeholders’ expectations.

The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2181.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

Medley, Inc. Announces Merger with ASFON TRUST NETWORK Inc.

Medley, Inc. announced a merger with its wholly owned subsidiary, ASFON TRUST NETWORK Inc., to enhance synergies and accelerate growth. The merger will result in an extraordinary loss due to the extinguishment of tie-in shares, but it is expected to strengthen the company’s operations and market positioning.

The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2374.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

Medley, Inc. Completes Strategic Share Repurchase

Medley, Inc. has completed a share repurchase program, acquiring 187,300 common shares for approximately 457 million yen through market transactions on the Tokyo Stock Exchange. This move is part of Medley’s flexible capital policy aimed at adapting to market conditions and optimizing shareholder returns, with the company indicating potential future repurchases.

The most recent analyst rating on (JP:4480) stock is a Buy with a Yen5600.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.